ARTICLE | Clinical News
AZD5363: Phase I data
April 15, 2013 7:00 AM UTC
Data from a pair of open-label, dose-escalation, European and Japanese Phase I trials in a total of 92 patients showed that twice-daily oral AZD5363 led to 2 partial responses - 1 ovarian cancer patie...